Barclays upgraded Emerson (EMR) to Equal Weight from Underweight with a price target of $127, up from $125, following the Q3 report. The firm believes the process markets will be “fairly steady” into 2026. Market expectations for Emerson’s process and industrial capex outlook now appear more realistic, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR: